021-51111890
购物车（）
sales@molnova.cn
Tasquinimod
CAS No. 254964-60-8
Tasquinimod ( ABR-215050;ABR215050;ABR 215050 )
产品货号. M13764 CAS No. 254964-60-8
An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥518 | 有现货 |
|
| 5MG | ￥778 | 有现货 |
|
| 10MG | ￥1110 | 有现货 |
|
| 25MG | ￥1863 | 有现货 |
|
| 50MG | ￥2754 | 有现货 |
|
| 100MG | ￥4212 | 有现货 |
|
| 500MG | ￥9396 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tasquinimod
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.
-
产品描述An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM; inhibits colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1α.Prostate cancer Phase 3 Clinical
-
同义词ABR-215050;ABR215050;ABR 215050
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC4
-
研究领域Cancer
-
适应症Prostate Cancer
化学信息
-
CAS Number254964-60-8
-
分子量406.36
-
分子式C20H17F3N2O4
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 42 mg/mL
-
SMILESO=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3
-
化学全称3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Isaacs JT, et al. Prostate. 2006 Dec 1;66(16):1768-78.
2. Olsson A, et al. Mol Cancer. 2010 May 17;9:107.
3. Dalrymple SL, et al. Prostate. 2012 May 1;72(6):638-48.
4. Isaacs JT, et al. Cancer Res. 2013 Feb 15;73(4):1386-99.
2. Olsson A, et al. Mol Cancer. 2010 May 17;9:107.
3. Dalrymple SL, et al. Prostate. 2012 May 1;72(6):638-48.
4. Isaacs JT, et al. Cancer Res. 2013 Feb 15;73(4):1386-99.
产品手册
关联产品
-
KA2507
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
-
Givinostat
Givinostat or gavinostat, aslo known as ITF2357, is a potent and orally active histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
-
Detomidine HCl
Detomidine HCl produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.
